| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(4 years from now) | |
| US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(4 years from now) | |
| US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(7 years from now) | |
| US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(4 years from now) | |
| US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(7 years from now) | |
Brenzavvy is owned by Theracosbio.
Brenzavvy contains Bexagliflozin.
Brenzavvy has a total of 6 drug patents out of which 0 drug patents have expired.
Brenzavvy was authorised for market use on 20 January, 2023.
Brenzavvy is available in tablet;oral dosage forms.
Brenzavvy can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Drug patent challenges can be filed against Brenzavvy from 20 January, 2027.
The generics of Brenzavvy are possible to be released after 14 May, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
BRENZAVVY family patents
